Literature DB >> 21999122

American Society of Clinical Oncology 2011 CNS tumors update.

Manmeet S Ahluwalia1.   

Abstract

A number of important studies were presented at the CNS tumors section of the 2011 American Society of Clinical Oncology Annual Meeting. There was particular interest in RTOG 0525, a Phase III study of newly diagnosed glioblastoma treated with different schedules of temozolomide. Prognostic factors for response, survival and chemotherapy-related toxicity in primary CNS lymphoma from the German randomized Phase III trial in newly diagnosed primary CNS lymphoma were also presented.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21999122     DOI： 10.1586/era.11.151

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  6 in total

1.  Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.

Authors:  David G Brachman; Stephanie L Pugh; Lynn S Ashby; Theresa A Thomas; Erin M Dunbar; Samir Narayan; H Ian Robins; Joseph A Bovi; Jason K Rockhill; Minhee Won; Walter P Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

2.  Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.

Authors:  Shanshan Jiang; Qihong Rui; Yu Wang; Hye-Young Heo; Tianyu Zou; Hao Yu; Yi Zhang; Xianlong Wang; Yongxing Du; Xinrui Wen; Fangyao Chen; Jihong Wang; Charles G Eberhart; Jinyuan Zhou; Zhibo Wen
Journal:  Eur Radiol       Date:  2017-12-12       Impact factor: 5.315

Review 3.  The spectrum of vaccine therapies for patients with glioblastoma multiforme.

Authors:  Laura K Aguilar; Mariel Arvizu; Estuardo Aguilar-Cordova; E Antonio Chiocca
Journal:  Curr Treat Options Oncol       Date:  2012-12

Review 4.  Incorporation of prognostic and predictive factors into glioma clinical trials.

Authors:  Derek R Johnson; Evanthia Galanis
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

Review 5.  Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.

Authors:  Niklas Thon; Simone Kreth; Friedrich-Wilhelm Kreth
Journal:  Onco Targets Ther       Date:  2013-09-27       Impact factor: 4.147

6.  Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).

Authors:  Arshad A Pandith; Iqbal Qasim; Wani Zahoor; Parveen Shah; Abdul R Bhat; Dheera Sanadhya; Zafar A Shah; Niyaz A Naikoo
Journal:  Sci Rep       Date:  2018-04-30       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.